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Abstract 
Background: A previous report has shown that LGALS3BP (also known as 90K or Mac-2 BP) has antitumor activity in 
colorectal cancer (CRC) via suppression of Wnt signalling with a novel mechanism of ISGylation-dependent ubiquit-
ination of β-catenin. The role of LGALS3BP in CRC prognosis was investigated.
Methods: The role of LGALS3BP on CRC progression and clinical prognosis was analyzed by combining cell cultures, 
in vitro assays, and immunohistochemistry.
Results: Silencing of LGALS3BP in HCT-116 human colon cancer cells resulted in enhanced β-catenin expression 
that was reversed by addition of human recombinant LGALS3BP. Moreover, intra-tumor delivery of LGALS3BP reduced 
tumor growth of xenografts originating from LGALS3BP-silenced HCT-116 cells. Finally, in a series of 196 CRC patients, 
LGALS3BP expression in tumor tissue associated with clinical outcome. Patients with high LGALS3BP expression had 
lower risk of relapse and a longer overall survival time than those with low LGALS3BP expression. Multivariate analyses 
confirmed LGALS3BP expression status as the only independent prognostic factor of survival.
Conclusions: These results provide evidence that low expression of LGALS3BP participates in malignant progression 
of CRC and implicates poor prognosis, highlighting its augmentation as a potential therapeutic approach.
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Background
Colorectal cancer is a major cause of cancer-related mor-
tality worldwide, causing ~500,000 deaths annually. Fol-
lowing curative resection, there is a considerable risk 
of recurrence in patients with stage II and III disease. 
Recurrence occurs in ~20% of stage II patients and ~50% 
of the stage III patients may be cured with surgery alone 
[1–3]. Therefore, it is critical to identify patients with a 
high risk of recurrence.
LGALS3BP is a large oligomeric, highly glycosylated 
protein composed of ≈90  kDa subunits that was origi-
nally identified as a tumor-secreted antigen [4] and as 
a ligand of the lactose-specific S-type lectin, galectin-3 
(formerly Mac-2) [5]. Whereas the bio-physiological 
activity of LGALS3BP is not yet well defined, accumulat-
ing evidence has shown that the protein may be involved 
in cancer growth and progression [6]. Notably, signifi-
cantly elevated expression of LGALS3BP in the serum or 
tumor tissue has been found to be associated with poor 
clinical outcome in patients with breast carcinoma [7, 8], 
hepatocellular carcinoma [9, 10], pleural mesothelioma 
[11], pancreatic carcinoma [12], non-small cell lung car-
cinoma [13] and neuroblastoma [14]. In contrast, posi-
tive effects of LGALS3BP on cancer prognosis have also 
been reported [15, 16]. Recently, Lee et  al. [16] found 
that LGALS3BP has antitumor activity in colorectal can-
cer (CRC) cells via suppression of Wnt signalling with a 
novel mechanism of ISGylation dependent ubiquitina-
tion of β-catenin. The authors also found that LGALS3BP 
knockdown resulted in increased tumor growth and 
metastasis formation in a syngeneic mouse colon tumor 
model. In the present study, we confirm and extend these 
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findings by showing that LGALS3BP knock-down human 
CRC cells formed large tumors when implanted in nude 
mice and that intra-tumor delivery of human recombi-
nant LGALS3BP induced regression of established CRC 
xenografts. In addition, we show that high LGALS3BP 
expression in the tumor tissue is associated with a longer 
disease-free and overall survival in CRC patients.
Methods
Cell lines and culture
The HCT-116 human colon cancer cell line was obtained 
from ATCC (Rockville, MD, USA). Cells were main-
tained in culture for fewer than 6 months after thawing. 
Cells were maintained in RPMI-1640 medium (Invitro-
gen, Carlsbad, CA. USA) with 10% heat-inactivated fetal 
bovine serum (FBS; Invitrogen), l-glutamine and antibi-
otics (Sigma Aldrich Corporation, St. Louis, MO, USA). 
The cells were maintained in a humidified chamber with 
95% air and 5% CO2 at 37°C.
LGALS3BP gene knockdown
A 21-nucleotide sequence corresponding to nucleotide 
2216–2236 of human LGALS3BP mRNA (NCBI Acces-
sion NM-005567.3) or a 21-nucleotide sequence with no 
significant homology to any mammalian gene sequence 
serving as a non-silencing control (OligoEngine, Hercu-
les, CA, USA) were inserted into the pSUPER.retro.puro 
(OligoEngine). After transformation of DH5α competent 
cells (Invitrogen), the recombinant plasmids were con-
firmed by PCR amplification, restriction enzymes diges-
tion and DNA sequencing.
The generation of HCT-116 knock-down cells was per-
formed according to the methods described in our previ-
ous report [17].
Enzyme‑linked immunosorbent assay (ELISA)
A sandwich-type ELISA (Diesse, Siena, Italy) was used 
to determine the concentration of LGALS3BP in the 
conditioned medium of control- and LGALS3BP-knock-
down HCT-116 cells. Culture medium was used a blank 
control.
Generation of recombinant LGALS3BP
Human recombinant LGALS3BP was immunoaffinity-
purified [18] from serum-free supernatant of human 
embryonic kidney EBNA-293 cells (Invitrogen) trans-
fected with LGALS3BP cDNA [19]. In brief, the super-
natant of the cells (2 L) added with Pefabloc (Boehringer 
Mannheim, Germany) and EDTA (1 and 0.4 mM, respec-
tively), was concentrated with a Vivaflow 200 system 
(Sartorius Biotech Goettingen, Germany) to 50  mL and 
passed over an affinity column made of 20  mg of the 
anti-LGALS3BP antibody (SP-2) covalently coupled to 
12 mL of cyanogen bromide activated Sepharose CL-4B 
(Sigma Aldrich Corporation). After washing the col-
umn with PBS, bound proteins (>95% LGALS3BP) were 
eluted with 20 mL of 0.1 M glycine buffer, pH 2.8. Pooled 
LGALS3BP-containing fractions were dialysed against 
PBS and stored in small aliquots at −80°C. SDS-PAGE 
showed a major band (90%) migrating at ~97  kDa. The 
endotoxin level of the final preparation was <5 EU/μg, as 
evaluated by the Lymulus Amebocyte Lysate (LAL) test 
(Clongen Labs, Germantown, MD, USA).
Confocal microscopy
HCT-116shctrl and HCT-116shLGALS3BP were seeded 
on glass coverslips and allowed to grow for 24 h at 37°C 
in 5% CO2. Cells were incubated with LGALS3BP (10 μg/
mL) for the indicated times, fixed with 4% paraformal-
dehyde for 15  min at room temperature, permeabilized 
with 0.25% Triton X-100 for 5  min and blocked with 
0.1% bovine serum albumin for 1 h at room temperature. 
Coverslips were then incubated for 2  h at room tem-
perature with a mouse anti β-catenin antibody (clone 
14/β-catenin, Becton–Dickinson, Franklin Lakes, NJ, 
USA) followed by Alexa-Fluor 488 goat anti-mouse sec-
ondary antibody (Molecular Probes, Life Technologies, 
Paisley, UK). DRAQ5 (Vinci Biochem, Firenze, Italy) 
was used to visualize nuclei. Images were acquired with 
a Zeiss LSM 510 meta-confocal microscope (Zeiss, 
Oberkochen, Germany) using 488 and 633  nm lasers. 
Detector gain voltages and pinhole were set at the begin-
ning of the experiment and maintained constant during 
the acquisition of all samples.
Western blotting
Cells were lysed with RIPA buffer containing protease 
and phosphatase inhibitors (Sigma Aldrich Corpora-
tion). Lysates were clarified by centrifugation at 14,000× 
rpm for 15 min at 4°C, subjected to 10% SDS-PAGE and 
Western blotting using a mouse anti-β-catenin antibody 
(Becton–Dickinson), a mouse anti-actin antibody (Sigma 
Aldrich Corporation) or a mouse monoclonal antibody 
against LGALS3BP (3C12.2). Incubation was performed 
overnight at 4°C. After washing with PBS containing 0.1% 
Tween-20, blots were incubated with a goat anti-mouse 
HRP-conjugated IgG as a secondary antibody (Biorad, 
Berkeley, CA, USA) at room temperature for 2  h and 
developed with a chemiluminescence detection system 
(Perkin-Elmer, Waltham, MA, USA).
Tumor xenografts
All animal studies were approved by the Institutional 
Animal Ethics Committee. Female athymic (nu+/nu+) 
mice (6-week old) (Charles River Laboratories, Milan, 
Italy) were acclimatized for 2  weeks before the start of 
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the experiments and housed under specific pathogen-
free conditions. Mice were given ad  libitum access to 
food and water. HCT-116shLGALS3BP or HCT-116shc-
trl cells (5 × 106) were implanted s.c. into the right flank 
of the mice (15 mice for HCT-116shLGALS3BP cells; 9 
mice for HCT-116shctrl cells). Tumor volume was moni-
tored twice a week for a total of 6 weeks by a caliper and 
calculated using the following formula: tumor volume 
(mm3) =  (length ×  width2)/2. In another set of experi-
ments, animals harboring HCT-116shLGALS3BP xeno-
grafts (approximately 200  mm3) were randomly divided 
into two groups of 10 animals each; one group was 
injected intra-tumorally with 50 μL LGALS3BP (100 μg), 
while the other group was injected with the same vol-
ume of PBS. Injections were made twice a week. Animals 
received a total of nine injections.
Patient information and tissue specimens
A total of 196 assessable CRCs were collected from 
patients who received surgical treatment at the Univer-
sity “G. D’Annunzio”, Chieti, Italy between 1996 and 
2010. Inclusion criteria were: (a) CRC primary cancer; (b) 
CRC with pathological diagnosis; (c) informed consent or 
waiver of consent; (d) age ≥18 years; (e) receipt of at least 
one follow-up within 5 years. To avoid possible interac-
tions between response to treatment and LGALS3BP 
status, only patients not receiving any adjuvant systemic 
therapy were included in the study. The clinico-path-
ological classification and the stage were determined 
according to the American Joint Committee on Cancer 
(AJCC) TNM staging system. Each lesion was graded his-
tologically according to the WHO classification criteria. 
Patients and tumor characteristics are summarized in 
Table 1. The median follow-up was of 45 months (range 
1–176  months). During follow-up, 63 out of 196 (32%) 
patients developed relapses and deaths were observed 
in 50 out of 196 (26%) patients. The study was reviewed 
and approved by Institutional Research Ethics Commit-
tee and written informed consent was obtained from all 
patients.
Immunohistochemistry
For the evaluation of β-catenin expression in mouse 
xenografts, formalin-fixed and paraffin-embedded 
tumor xenografts of HCT-116shctrl (n  =  9) and HCT-
116shLGALS3BP (n = 15), were sectioned at 5 μm and 
stained using anti-human β-catenin mouse monoclo-
nal antibody (BD Transduction Laboratories) at 1:3,000 
dilution for 60 min. Antigen retrieval was performed by 
microwave treatment at 750 W for 10 min in 10 mmol/L 
sodium citrate buffer (pH 6.0). EnVision kit (K4001, 
Dako, Glostrup, Denmark) was used for signal amplifi-
cation. In control sections the specific primary antibody 
was replaced with isotype-matched immunoglobulins 
(Dako).
Tissue microarrays (TMA) were constructed by 
extracting 2-mm diameter cores of histologically con-
firmed neoplastic areas from 196 invasive primary 
human CRC, as previously detailed [20] TMA sec-
tions were stained using the monoclonal mouse anti-
human LGALS3BP as previously reported [8]. Staining 
of LGALS3BP was quantified as percentage of stained 
tumor cells. To dichotomize LGALS3BP expression, a 
cut-off value of 69% was chosen, which corresponded to 
the 75th percentile. Therefore, tumors whose percent-
age of stained cells was ≤69% were considered as low 
LGALS3BP, all the others as high LGALS3BP. Immuno-
histochemical analysis was done by two pathologists (MP, 
RL) who were blinded to the clinical data of the patients.
Statistical methods
Two-tailed unpaired T-test was used to compare the sta-
tistical significance of the differences in data from two 
groups, where appropriate. Disease-free survival (DFS) 
was defined as the time from surgery to the first one of 
the following events: recurrence at local or distant sites, 
or intercurrent death without recurrence. Overall sur-
vival (OS) was defined as the interval between the date 
of surgery and date of death or the last known follow 
Table 1 Clinico-pathological data of 196 patients with CRC
Number of cases (%)
Gender
 Male 125 (64)





 Colon 161 (82)
 Rectal 35 (18)
Clinical stage
 1 14 (7)
 2 155 (80)
 3 25 (13)
TOT 194
Pathological differentiation
 Well 16 (8)
 Moderate 163 (84)
 Poor 16 (8)
TOT 195
LGALS3BP
 Low 151 (77)
 High 45 (23)
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up. Survival curves were plotted by the Kaplan–Meier 
method and compared using the log-rank test. The asso-
ciation of LGALS3BP expression with outcome, adjusted 
for other prognostic factors, was tested by Cox’s pro-
portional hazards model. The following covariates were 
included in the multivariate models: gender, tumor loca-
tion, grade and LGALS3BP status. All statistical analyses 
were performed using by the SPSS 15.0 statistical soft-
ware package (SPSS Inc., Chicago, IL, USA); p < 0.05 was 
considered as statistically significant.
Results
LGALS3BP‑silenced CRC cells grow larger tumors, an effect 
which is reversed by intratumor injection of LGALS£BP
To investigate the role of LGALS3BP on tumor growth, 
short hairpin RNA constructs were generated to 
stably knock-down LGALS3BP in HCT-116 cells (HCT-
116shLGALS3BP). A scramble siRNA was also trans-
fected into cells as negative control (HCT116shctrl). 
After transfection, expression of LGALS3BP protein 
was assessed by Western blotting (Fig. 1 box) and ELISA 
assay on the conditioned medium of both cell lines 
(185.5 ng/mL in HCT-116shctrl vs. 40.1 ng/mL in HCT-
116shLGALS3BP cells).
As expected from the results of a previous report 
showing degradation of β-catenin after forced expression 
of LGALS3BP [16], stable knock-down of LGALS3BP 
led to a marked increase of β-catenin, as evaluated by 
confocal microscopy (Fig.  1a) and western blot analy-
sis (Fig.  1b). Moreover, exposure of silenced cells to 
10 μg/mL LGALS3BP resulted in a significant decrease 
of β-catenin expression both in HCT-116shctrl and 
Fig. 1 LGALS3BP downregulates β-catenin expression in human colon cancer cells. Expression of β‐catenin in HCT‐116shCTRL and HCT‐
116shLGALS3BP HCT‐116 cells after stimulation with LGALS3BP (10 μg/mL) for the indicated times. a Confocal microscopy images showing 
β-catenin (green) and nuclei (blue) (scale bar 20 μm). In the box, western blotting analysis showing LGALS3BP expression in shCtrl and shLGALS3BP 
cells. b Representative western blots showing β-catenin expression. Actin was used as an internal loading control. c Histograms depict the band 
intensity ratio β-catenin/actin as measured by Image J software. Data are representative of at least three independent experiments.
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HCT-116shLGALS3BP cells. After 24  h, the expression 
level of β-catenin in silenced cells was similar to the basal 
level of vector control cells.
To examine the function of LGALS3BP in tumorigen-
esis in  vivo, we implanted s.c. HCT-116 vector control 
and LGALS3BP knock-down cells into the flanks of nude 
mice and monitored tumor growth for up to 6 weeks. A 
significant reduction in growth was seen in tumors deriv-
ing from vector control cells as compared to those deriv-
ing from LGALS3BP knock-down cells (58% reduction 
of control group compared to LGALS3BP knock-down 
group; p < 0.05; Fig. 2a). To investigate whether the higher 
growth rate of LGALS3BP knock-down tumors was 
linked to increased β-catenin expression, we performed 
immunohistochemistry. When compared to tumors 
deriving from HCT-116 vector control, those from 
LGALS3BP knock-down cells displayed higher expres-
sion of β-catenin, preferentially at plasma membrane 
level. By independent-sample t-test, β-catenin was found 
to be more expressed in LGALS3BP knock-down HCT-
116 cells (24.1% ±  5.3 SE; mean percentage ±  standard 
error) compared to tumors deriving from HCT-116 vec-
tor control (9.8% ± 4.7 SE), with a trend toward statistical 
significance (p = 0.079). Examples of β-catenin staining, 
Fig. 2 LGALS3BP knock-down affects growth of tumor xenografts and is associated with a reduction in β-catenin expression. a HCT-116shctrl and 
HCT-116shLGALS3BP cells were implanted s.c. into the right flank of female nude mice (9 mice for HCT-116shctrl; 15 mice for HCT-116shLGALS3BP). 
Tumor growth was assessed as described in “Methods”. *p < 0.05. b Examples of immunohistochemical staining of β-catenin in HCT-116shctrl and 
HCT-116shLGALS3BP xenografts (scale bar 20 μm). c Animals harboring HCT-116shLGALS3BP xenografts (approximately 200 mm3) were randomly 
divided into two groups (indicated by the arrow); tumors from one group were injected intra-lesionally with 100 μg LGALS3BP in 50 μL PBS, the 
other injected with the same volume of PBS. Injections were made twice a week. Tumor growth was assessed as described in “Methods”. (*p < 0.05).
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preferentially at plasma membrane level, of tumors deriv-
ing from vector control and LGALS3BP-knock down 
cells are illustrated in Fig. 2b. Overall, these results sug-
gest that the increased tumorigenic hallmarks of HCT-
116 cells following LGALS3BP silencing was linked to 
an increase expression of β-catenin, both in  vitro and 
in vivo.
To confirm that LGALS3BP has a suppressive role in 
CRC growth, tumors from HCT-116 LGALS3BP knock-
down cells were injected intra-lesionally with 100  μg 
LGALS3PBP in 50 μL PBS or the same volume of PBS (as 
a control) twice a week; starting from the fifth injection 
of LGALS3BP, a significant reduction in tumor growth 
was observed (Fig. 2c).
Correlation of LGALS3BP expression with patient outcome
LGALS3BP protein expression was evaluated by immu-
nohistochemistry in 196 paraffin-embedded, archival pri-
mary colorectal cancer tissues. According to the cut-off, 
low LGALS3BP expression (staining of ≤69% of the neo-
plastic cells) was detected in 151/196 (77%) CRC tumors, 
while high LGALS3BP expression was detected in 45/196 
(23%). LGALS3BP staining was cytoplasmic with dif-
fuse and granular patterns and substantially confined to 
the neoplastic compartment. Examples of low and high 
expression of LGALS3BP are shown in Fig.  3. Low and 
high LGALS3BP expressing tumors did not differ signifi-
cantly for the distribution of clinic-pathological variables 
evaluated (data not shown).
Eight out of 45 (17.8%) patients with high LGALS3BP 
expressing tumors and 55 out of 151 (36.4%) patients 
with low LGALS3BP expressing tumors had a disease 
relapse. Analysis of Kaplan–Meier curves showed that 
patients with high LGALS3BP expressing tumors had 
a higher DFS rate than patients with low LGALS3BP 
expressing tumors (Fig.  4a). Multivariate analysis 
adjusted for the other prognostic factors showed that 
LGALS3BP status was the only significant prognos-
tic parameter of DFS (HR 2 80, 95% CI 1.27–6.18; 
p = 0.011) (Table 2).
Patients whose tumors expressed low LGALS3BP had 
a shorter OS than those with high LGALS3BP expression 
(median OS 135  months vs. not reached, respectively; 
p < 0.002; Fig. 4b). The overall five-year cumulative sur-
vival rate was 68.5% in cases with low LGALS3BP expres-
sion and 91% in cases with high LGALS3BP expression. 
Furthermore, multivariate analyses indicated that 
LGALS3BP expression was the only significant prognos-
tic factor of OS (HR 4.07, 95% CI 1.45–11.45; p = 0.008) 
(Table 2).
Discussion
This is the first study on the prognostic relevance of the 
LGALS3BP in CRC patients. We demonstrated that 
high LGALS3BP expression in primary tumor tissue 
correlated with a better disease-free and overall sur-
vival outcome, whereas low LGALS3BP expression cor-
related with a poorer survival outcome. On multivariate 
analysis, LGALS3BP expression was an independent 
prognostic factor, suggesting that the protein may be 
a prognostic factor for survival in CRC patients. Since 
none of the patients received adjuvant systemic therapy, 
possible interactions between response to treatment and 
LGALS3BP status can be excluded, and the marker influ-
ence on survival can be attributed exclusively to its rela-
tionship with the natural history of the disease.
Fig. 3 Examples of LGALS3BP staining in CRC. Immunohistochemical staining showing high (left) and low (right) expression of LGALS3BP in a case 
of CRC (original magnification ×400). Scale bar 20 μm.
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The role of LGALS3BP in cancer prognosis remains 
equivocal. The protein has been reported to have both 
negative and positive influences on the prognosis of vari-
ous cancers. Most of the studies have shown that high 
LGALS3BP levels are associated with shorter survival, 
the occurrence of metastasis or a reduced response to 
chemotherapy [7, 11, 13, 21–24]. In contrast, positive 
effects of LGALS3BP have also been found. For exam-
ple, engineered enhancement of LGALS3BP expression 
resulted in significant tumor growth inhibition [25] and 
high levels of LGALS3BP expression in tumor tissue were 
associated with a favorable outcome in a series of patients 
with Ewing’s sarcoma [15]. The mechanism underlying 
positive and negative influences of LGALS3BP on the 
prognosis of various cancers is not understood, but may 
be related to the multi-domain nature of the protein and 
its ability to bind to different ligands, including galectins, 
in particular galectin-3 and 1 [26], endosialin [27] and 
tetraspanins [28] in different tumor tissues.
Lee et al. [16] recently reported LGALS3BP-dependent 
suppression of Wnt signalling with a novel mechanism of 
ISGylation-dependent ubiquitination of β-catenin when 
it interacts with the tetraspanins CD9 and CD82. The 
authors examined the expression patterns of LGALS3BP, 
CD9, CD82, β-catenin and galectins in serial colon tissue 
sections in patients with stage I and IV CRC and also in 
metastatic liver tissues, and found that LGALS3BP, CD9 
and CD82 were higher in the cancer tissues from stage I 
than in the stage IV and in the adjacent normal hepatic 
tissues than in the invading colon cancer cells. They spec-
ulated that a lower expression of LGALS3BP as well as 
CD9/CD82 in CRC tissues is a marker of poor prognosis 
of CRC.
Our results suggest that LGALS3BP reduction of 
β-catenin levels could represent a mechanism underly-
ing LGALS3BP prognostic significance in CRC. Indeed 
LGALS3BP-silenced HCTI16 cells showed higher 
β-catenin levels as compared to control silenced cells 
(Fig.  1a, b) and developed larger tumors when injected 
into nude mice (Fig. 2a). The role of LGALS3BP as a sup-
pressor of tumor growth was further substantiated by 
the finding that a significant tumor regression could be 
achieved with LGALS3BP injected directly into xeno-
grafts originating from LGALS3BP-silenced HCTI16 
cells (Fig. 2c).
Fig. 4 Correlation of LGALS3BP expression with patient outcome. Kaplan–Meier disease free survival (a) and overall survival (b) analysis among 196 
CRC patients according to the expression of LGALS3BP in tumor tissue (p < 0.006 and p < 0.002, respectively). Green and blue lines indicate high and 
low expression of LGALS3BP, respectively.
Table 2 Multivariate analysis of various prognostic param-
eters in patients with colorectal cancer
Cox-regression analysis.
Hazard ratio 95% CI P
Disease free survival
 Gender (female vs. male) 1.06 0.62–1.79 0.84
 Location (rectum vs. colon) 1.49 0.82–2.73 0.19
 Tumor grade (2–3 vs. 1) 1.73 0.54–5.54 0.36
 LGALS3BP (low vs. high) 2.80 1.27–6.18 0.011
Overall survival
 Gender (female vs. male) 1.11 0.61–2.03 0.74
 Location (rectum vs. colon) 1.52 0.77–3.02 0.23
 Tumor grade (2–3 vs. 1) 1.84 0.44–7.61 0.40
 LGALS3BP (low vs. high) 4.07 1.45–11.45 0.008
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Conclusion
In sum, our results suggest that a reduced expression of 
LGALS3BP is one of the factor responsible of the malig-
nant progression of CRC and implicates poor prognosis 
This notion could represent a potential strategy for pre-
vention or treatment of CRC growth and progression.
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